Volume 10, Number 11—November 2004
THEME ISSUE
ICEID & ICWID 2004
International Conference on Women and Infectious Diseases (ICWID)
Rubella Elimination and Improving Health Care for Women
Carlos Castillo-Solórzano* and Jon Kim Andrus*
Table
Rubella and congenital rubella eliminationa,b
| Time | Country | Target group | Vaccine used | Coverage achieved (%) |
|---|---|---|---|---|
| 1998–2001 | English-speaking Caribbean 18 countries | 2.16 million men/women 20–29 y | MR and MMR | Average 80c Range 64–97 |
| 1999 | Chile | 2.5 million women 10–29 y | R | 98 |
| 2001 | Costa Rica | 1.6 million men/women 15–39 y | MR | 98c |
| 2001 2002 | Brazil 13 states 11 states | 27 million, women 12–39 yd | MR | 95 |
| 2002 | Honduras | 3.3 million men 5–39 y women 5–49 y | MR | 98 Men 95 Women 98 |
| 2004 | El Salvador | 2.8 million men/women 15–39 y | MR | 99 Men 93 Women 99 |
| 2004 | Ecuador | 4.8 million men/women 16–39 y | MR | 100 Men 100 Women 100 |
aCRS, congenital rubella syndrome; R, rubella containing vaccine; MR, double viral vaccine, measles/rubella containing vaccine; MMR, triple viral
vaccine.
bSource: 12–18.
cMen/women vaccinated in equal proportions.
dSome states modified the age of the group based on the year of the vaccine introduction.
Page created: May 04, 2011
Page updated: May 04, 2011
Page reviewed: May 04, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.